In the US Schizophrenia Care and Assessment Program (US-SCAP) study, patients with a recent relapse demonstrated a relative relapse risk of 4.23 during the 1-year study (P<0.001) compared to patients who experienced no relapse in the previous 6 months.[Ascher-Svanum et al., 2010(1)]
Patients were 18 years of age or older and had been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.[Ascher-Svanum et al., 2010(2)]
Compared to patients who did not experience prior relapse, patients with prior relapse incurred significantly higher total annual direct mental health care costs during the 1-year study period, which were nearly 3 times higher for those who relapsed ($33,187) compared with those who did not ($11,771, P<0.01).[Ascher-Svanum et al., 2010(2)]
References:
Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010; 10: 2.[Additional file 3: Table S3. Logistic regression analyses of relapse predictors for the 1,557 participants and by relapse status]
Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010; 10:2. (2)